Treatment-resistant depression

USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases

Retrieved on: 
Wednesday, June 22, 2022
CNS, Amyotrophic lateral sclerosis, US Foods, Lists of diseases, Security (finance), FDA, Patent, Traffic barrier, CEO, Company, TNF, TRD, USPTO, Degenerative disease, U.S. Securities and Exchange Commission, Cancer, Research, Private Securities Litigation Reform Act, Neurodegeneration, Inflammatory demyelinating diseases of the central nervous system, Disease, Marketing, NASDAQ, Treatment-resistant depression, Central nervous system, Inflammation, Food, OF, BBB, Patient, AD, ALS, GLOBE, Natural killer cell, Pharmaceutical industry

11,365,229 for METHODS OF TREATING NEUROLOGICAL DISEASES, a patent directed to use of Dominant Negative Tumor Necrosis Factor (DN-TNF) variants, such as the Companys XPro, by peripheral administration for crossing the blood-brain barrier (BBB) and treating diseases of the Central Nervous System (CNS).

Key Points: 
  • 11,365,229 for METHODS OF TREATING NEUROLOGICAL DISEASES, a patent directed to use of Dominant Negative Tumor Necrosis Factor (DN-TNF) variants, such as the Companys XPro, by peripheral administration for crossing the blood-brain barrier (BBB) and treating diseases of the Central Nervous System (CNS).
  • The patent is currently set to provide coverage through September 10, 2033, subject to a possible patent term extension if requested by the Company and approved by the USPTO under 35 U.S.C.
  • This patent is the product of real-life data using DN-TNF in both pre-clinical studies and the completed human Phase I study in Alzheimers Disease.
  • Because the drug is self-administered as a once-a-week subcutaneous injection, the patients or their care-givers can administer XPro at home.

First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)

Retrieved on: 
Wednesday, June 8, 2022
Analgesic, Treatment-resistant depression, Panic disorder, PTSD, VC, Anxiety, TRD, AI, MDD, Workforce, GLOBE, Patient, Chrono, Aggression, Depression, MADRS, Lists of diseases, Safety, Pharmaceutical industry, Ketamine

MUNICH, Germany, June 08, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), together with Develco pharma, today announced the dosing of the first patient in their second Phase 2 trial with oral prolonged-release Ketamine (KET01) for Treatment-Resistant Depression.

Key Points: 
  • The trial will assess the efficacy, safety, and tolerability of add-on treatment with Ketamine hydrochloride prolonged-release tablets (KET01) in patients suffering from Treatment-Resistant depression (TRD).
  • The trial is expected to confirm the results of the previous trial, with early-onset of efficacy, showing placebo-level dissociative side effects, and excellent tolerability, furthering the take-at-home potential of this novel treatment.
  • The Ketabon program, which is a joint venture between HMNC Brain Health and Swiss-based Develco Pharma, funded the trial.
  • Clinical development of oral prolonged-release Ketamine could also be potentially expanded into other indications, such as anxiety, aggression, PTSD, and panic disorder.

Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

Retrieved on: 
Thursday, June 2, 2022
Treatment-resistant depression, Principal investigator, CDSA, Removal of cannabis from Schedule I of the Controlled Substances Act, SAP, Disorder, Euro-Excellence Inc v Kraft Canada Inc, CSE, Company, Conference, Lists of diseases, Protocol, IV, Special access program, OTC, Psychotherapy, Drug prohibition law, Depression, Forward-looking statement, Minister of Health (Canada), CEO, News, Ketamine, Multimedia, Ta' Braxia Cemetery, Health Canada, Patient, Risk, MADRS, Chief scientific officer, Clinical trial, Controlled Drugs and Substances Act, Rapids, Psilocybin, Person, Safety, Pharmaceutical industry, Medical imaging, Risk management, Audit, Research

(1) Symptoms of depression were assessed using the Montgomery-sberg depression rating scale (MADRS), a widely used and accepted scale for assessing depression.

Key Points: 
  • (1) Symptoms of depression were assessed using the Montgomery-sberg depression rating scale (MADRS), a widely used and accepted scale for assessing depression.
  • Braxia Scientific is a leader in providing access to innovative rapid acting treatments such as ketamine and psilocybin for people living with treatment resistant depression.
  • This ongoing clinical trial provides Canadians with immediate access to psilocybin for treatment resistant depression.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry

Retrieved on: 
Wednesday, May 18, 2022
Lists of diseases, Company, The American Journal of Psychiatry, Best practice, Implementation, News, American, Multimedia, American Psychiatric Association, OTC, Disorder, Rapids, Psilocybin, Review, Treatment, CDSA, Controlled Drugs and Substances Act, Depression, CSE, Esketamine, Forward-looking statement, Safety, Risk, Psychiatry, Euro-Excellence Inc v Kraft Canada Inc, Drug prohibition law, American Journal, Health Canada, Person, RWD, Removal of cannabis from Schedule I of the Controlled Substances Act, Treatment-resistant depression, Medical device, Pharmaceutical industry, Audit, Ketamine

Dr. McIntyre will participate in two discussions addressing members of the American Psychiatric Association.

Key Points: 
  • Dr. McIntyre will participate in two discussions addressing members of the American Psychiatric Association.
  • The presentation will also cover real-world data (RWD) with respect to efficacy, safety, and tolerability of ketamine treatment in adults with mood disorders.
  • For more information please visit the American Psychiatric Association Annual Meeting website.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

HMNC Brain Health to Webcast Live at the KCSA Virtual Psychedelics Conference

Retrieved on: 
Monday, April 25, 2022
Major depressive disorder, MDD, VC, Brain, Psychiatry, Treatment-resistant depression, TRD, AI, VIC, Security (finance)

HMNC Brain Healths management team will also participate in one-on-one meetings during the conference.

Key Points: 
  • HMNC Brain Healths management team will also participate in one-on-one meetings during the conference.
  • If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
  • To schedule a one-on-one meeting with HMNC Brain Healths management team, please contact KCSA Strategic Communications at [email protected] .
  • HMNC Brain Health now enters the next stage of its development with a large-scale licensing and fundraising agenda.

HMNC Brain Health to Participate in Upcoming Investor Conferences in April 2022

Retrieved on: 
Monday, April 11, 2022
Treatment-resistant depression, Brain, VC, TRD, MDD, AI, Major depressive disorder, Sales, Medical device

To schedule a one-on-one meeting with HMNC Brain Healths management team, please contact KCSA Strategic Communications at [email protected] .

Key Points: 
  • To schedule a one-on-one meeting with HMNC Brain Healths management team, please contact KCSA Strategic Communications at [email protected] .
  • HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company, pioneering the development of personalized therapies powered by its nascent AI platform and predictive companion diagnostics suite, leading to far shorter treatment durations and higher remission rates.
  • The company has operations in both the U.S. and Germany and is backed by a renowned global VC, several family offices, and a strategic healthcare investor.
  • HMNC Brain Health now enters the next stage of its development with a large-scale licensing and fundraising agenda.

HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD), suggesting antidepressant efficacy and showing Placebo-Level Dissociative Side Effects in Phase 2 oral prolonged-release Ketamine (KET01)

Retrieved on: 
Thursday, March 31, 2022
University of Zurich, Company, University, Aggression, MDD, Social psychiatry, Analgesic, Clinical trial, Treatment-resistant depression, Human, Lists of diseases, PTSD, Addiction, Coronavirus Scientific Advisory Board (Turkey), Ketamine, SCOPE, Psychiatry, Workforce, Grammatical mood, Safety, TRD, Chrono, VC, COVID-19, GLOBE, CRO, Anxiety, Department, Depression, Biozentrum University of Basel, Panic disorder, Patient, Major depressive disorder, Partnership, Pharmaceutical industry, MADRS, Schizophrenia, Psychotherapy

Potential first-in-class oral prolonged-release formulation of ketamine, KET01, suggests larger improvement in Montgomery-sberg Depression Rating Scale (MADRS) scores at 15 days compared to placebo.

Key Points: 
  • Potential first-in-class oral prolonged-release formulation of ketamine, KET01, suggests larger improvement in Montgomery-sberg Depression Rating Scale (MADRS) scores at 15 days compared to placebo.
  • Importantly, safety results from the trial demonstrated that KET01 was well tolerated, with no treatment-related serious adverse events reported.
  • The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma in Switzerland comprises an oral prolonged-release formulation of ketamine for TRD with minimal dissociative side effects.
  • Clinical development of oral prolonged-release ketamine could also be potentially expanded into other indications, such as anxiety, aggression, PTSD, and panic disorder.

Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation Psychedelics at Neuroscience 2021

Retrieved on: 
Monday, November 8, 2021
Psilocybin, Safety, Treatment-resistant depression, MSET, CSE, FSE, Society, Solution, SFN, Annual general meeting, Company, GLOBE, Drug discovery, Society for Neuroscience, Central nervous system, Pharmacokinetics, Pharmaceutical industry

The poster titled, Characterisation of Behavioural, Safety and Pharmacokinetics Properties of Psilocybin and Psilocin in Rodents, will be presented by Dr.

Key Points: 
  • The poster titled, Characterisation of Behavioural, Safety and Pharmacokinetics Properties of Psilocybin and Psilocin in Rodents, will be presented by Dr.
  • The presentation includes data on the pharmacokinetic/pharmacodynamic relationship between behaviors associated with the 5-HT2A receptor engagement induced by psilocybin and psilocin.
  • Mindsets previously announced efficacy and safety data on its psilocybin analog, MSP-1014, will be featured in the presentation.
  • Joseph Araujo, Chief Scientific Officer of Mindset, said, Mindset has developed an impressive library of preclinical data measuring the safety and efficacy of psychedelic drugs and our next-generation analogs.

Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its Novel Psilocybin-Inspired Clinical Candidate

Retrieved on: 
Thursday, September 9, 2021

MSP-1014 is a novel patent-pending drug candidate that, based on preclinical data, shows potential to be a safer second generation psilocybin-like therapy with decreased potential for side effects.

Key Points: 
  • MSP-1014 is a novel patent-pending drug candidate that, based on preclinical data, shows potential to be a safer second generation psilocybin-like therapy with decreased potential for side effects.
  • Psilocybin has demonstrated encouraging efficacy in treating TRD and End of Life Cancer Angst in a number of clinical studies and we believe our novel drug candidate, MSP-1014, represents a safer and more scalable evolution to its psilocybin predecessor, said James Lanthier, CEO of Mindset.
  • TRD represents a large and untreated population with of major depressive disorder sufferers resistant to presently available treatments1, while End of Life Angst is a major cause of depression and anxiety with limited treatment options.
  • Furthermore, MSP-1014 leverages Mindsets proprietary psilocybin synthesis process, enabling scale-up efficiency in manufacturing and positioning us well for progressing our novel drug candidate through to clinical trials.

New Study Published in Nature Journal, Translational Psychiatry, by Taliaz, Presents New Approach for Predicting Response to Depression Treatment

Retrieved on: 
Wednesday, July 21, 2021
Major depressive disorder, Health sciences, Psychiatry, Branches of biology, Psychiatric diagnosis, STAR*D, Treatment of depression, Pharmacogenomics, Antidepressant, Treatment-resistant depression

"Current practice for MDD treatment relies mainly on trial and error, with an estimated 4253% response rates for antidepressant use.

Key Points: 
  • "Current practice for MDD treatment relies mainly on trial and error, with an estimated 4253% response rates for antidepressant use.
  • The authors analyzed response patterns of more than 4500 patients to antidepressant medications in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study and the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS).
  • "This peer-reviewed publication corroborates our unique approach for the design of the PREDICTIX prediction algorithm to optimize treatment for mental health.
  • The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis.